nafamostat has been researched along with Diabetic Angiopathies in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| La Bonte, LR | 1 |
| Davis-Gorman, G | 1 |
| Stahl, GL | 1 |
| McDonagh, PF | 1 |
1 other study available for nafamostat and Diabetic Angiopathies
| Article | Year |
|---|---|
Complement inhibition reduces injury in the type 2 diabetic heart following ischemia and reperfusion.
Topics: Animals; Benzamidines; Blood Cell Count; Blood Glucose; Blood Pressure; CD11b Antigen; Cell Adhesion | 2008 |